Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq Other stock markets 01:30:00 16/04/2026 am IST			5-day change	1st Jan Change
21.73 ^USD	-1.90%		-0.78%	+0.98%

04:56pm	Roche launches new Elevidys study after feedback from European regulator	RE
07/04	RBC Adjusts Price Target on Sarepta Therapeutics to $19 From $18, Maintains Sector Perform Rating	MT

Transcript : Sarepta Therapeutics, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 01

Published on 03/04/2026 at 03:50 am IST - Modified on 03/05/2026 at 03:51 am IST

S&P Capital IQ

Presenter Speech
Ritu Baral (Analysts)

Thanks, everyone, for joining us at the Sarepta fireside chat at the 46th Annual TD Cowen Healthcare Conference. I'm covering analyst, Ritu Baral. And with us

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Sarepta Therapeutics, Inc.

04:56pm	Roche launches new Elevidys study after feedback from European regulator	RE
07/04	RBC Adjusts Price Target on Sarepta Therapeutics to $19 From $18, Maintains Sector Perform Rating	MT
26/03	Deutsche Bank Raises Price Target on Sarepta Therapeutics to $14 From $12, Keeps Sell Rating	MT
26/03	Wedbush Raises Price Target on Sarepta Therapeutics to $35 From $29, Keeps Outperform Rating	MT
26/03	Health Care Up Amid Deal Activity -- Health Care Roundup	DJ
25/03	Top Midday Gainers	MT
25/03	Sarepta Therapeutics, Inc. - Special Call
25/03	Sarepta Therapeutics Announces First Clinical Data from Sirna Pipeline Targeting FSHD1 and DM1	CI
25/03	Sarepta Therapeutics' Early Trial Results of siRNA Treatments Show High Muscle Concentrations in Neuromuscular Diseases	MT
25/03	Sarepta announces first clinical data from sirna pipeline targeting FSHD1 and DM1	RE
19/03	Sarepta Therapeutics Plans to Submit Supplemental New Drug Applications for Amondys 45, Vyondys 53	MT
19/03	Sarepta Therapeutics Provides Regulatory Update On Amondys 45 And Vyondys 53	CI
19/03	Taysha Gene Therapies, Inc. Appoints Brad Martin as Senior Vice President, Market Access and Value	CI
16/03	Sarepta Begins Enrollment in Study Evaluating Safety Regimen With Duchenne Therapy	MT
16/03	Sarepta announces that screening and enrollment are underway in Endeavor cohort 8 to evaluate enhanced immunosuppression regimen as part of Elevidys gene therapy for non-ambulant individuals with Duchenne	RE